Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,520.89 19.24 0.12%
S&P 500 1,880.74 5.35 0.29%
NASDAQ 4,157.01 30.04 0.73%
Ticker Volume Price Price Delta
STOXX 50 3,189.81 13.84 0.44%
FTSE 100 6,703.00 28.26 0.42%
DAX 9,548.68 4.49 0.05%
Ticker Volume Price Price Delta
NIKKEI 14,404.99 -141.28 -0.97%
TOPIX 1,164.90 -8.91 -0.76%
HANG SENG 22,562.80 53.16 0.24%

Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)



  Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule
                                  5635(c)(4)

PR Newswire

ALISO VIEJO, Calif., July 5, 2013

ALISO VIEJO, Calif., July 5, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc.
(NASDAQ: AVNR) today announced that on July 2, 2013, the Company approved the
grant of stock options to new employees to purchase 91,500 shares of common
stock in the aggregate.  The stock options were granted as inducements
material to the new employees entering into employment with Avanir, as
permitted under NASDAQ Listing Rule 5635(c)(4).

(Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO)

Avanir granted to 21 new employees an option to purchase shares of Avanir's
common stock with an exercise price equal to $4.54, the closing price per
share of Avanir's common stock as reported by NASDAQ on July 2, 2013, the date
of grant.  Each of the options is a non-qualified option and will vest
one-quarter of the underlying shares on the first anniversary of the grant
date and then with respect to the remaining shares quarterly thereafter over
the following three years, assuming in each case the employee remains
continuously employed by Avanir.

About Avanir Pharmaceuticals, Inc.
Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on
bringing innovative medicines to patients with central nervous system
disorders of high unmet medical need. As part of our commitment, we have
extensively invested in our pipeline and are dedicated to advancing medicines
that can substantially improve the lives of patients and their loved ones. For
more information about Avanir, please visit www.avanir.com.

AVANIR^® is a trademark or registered trademark of Avanir Pharmaceuticals,
Inc. in the United States and other countries.

^©2013 Avanir Pharmaceuticals, Inc. All Rights Reserved.

Avanir Investor & Media Contact
Ian Clements, PhD
ir@avanir.com 
+1 (949) 389-6700

SOURCE Avanir Pharmaceuticals, Inc.

Website: http://www.avanir.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement